NovoCure Limited (NASDAQ:NVCR) CEO Asaf Danziger sold 35,500 shares of the firm’s stock in a transaction dated Wednesday, September 13th. The shares were sold at an average price of $22.01, for a total transaction of $781,355.00. Following the completion of the transaction, the chief executive officer now directly owns 776,862 shares in the company, valued at $17,098,732.62. The sale was disclosed in a document filed with the SEC, which is available at this link.

Asaf Danziger also recently made the following trade(s):

  • On Thursday, September 14th, Asaf Danziger sold 37,272 shares of NovoCure Limited stock. The shares were sold at an average price of $22.01, for a total transaction of $820,356.72.
  • On Tuesday, July 11th, Asaf Danziger sold 7,383 shares of NovoCure Limited stock. The shares were sold at an average price of $19.95, for a total transaction of $147,290.85.
  • On Monday, July 10th, Asaf Danziger sold 274,359 shares of NovoCure Limited stock. The shares were sold at an average price of $18.07, for a total transaction of $4,957,667.13.
  • On Wednesday, July 5th, Asaf Danziger sold 155,088 shares of NovoCure Limited stock. The shares were sold at an average price of $18.14, for a total transaction of $2,813,296.32.
  • On Thursday, July 6th, Asaf Danziger sold 160,138 shares of NovoCure Limited stock. The shares were sold at an average price of $18.14, for a total transaction of $2,904,903.32.
  • On Monday, June 19th, Asaf Danziger sold 124,720 shares of NovoCure Limited stock. The shares were sold at an average price of $15.51, for a total transaction of $1,934,407.20.

NovoCure Limited (NVCR) traded down 4.40% on Friday, reaching $20.65. 1,138,966 shares of the company’s stock were exchanged. The company’s market cap is $1.84 billion. The firm has a 50 day moving average of $19.66 and a 200-day moving average of $14.33. NovoCure Limited has a 12-month low of $5.95 and a 12-month high of $22.30.

NovoCure Limited (NASDAQ:NVCR) last issued its earnings results on Thursday, July 27th. The medical equipment provider reported ($0.24) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.23) by ($0.01). NovoCure Limited had a negative net margin of 75.91% and a negative return on equity of 69.48%. The business had revenue of $38.38 million during the quarter, compared to analysts’ expectations of $42.20 million. Equities analysts expect that NovoCure Limited will post ($0.77) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “NovoCure Limited (NVCR) CEO Asaf Danziger Sells 35,500 Shares” was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/09/15/novocure-limited-nvcr-ceo-asaf-danziger-sells-35500-shares.html.

Several hedge funds have recently modified their holdings of the company. FMR LLC raised its stake in shares of NovoCure Limited by 50.4% in the 2nd quarter. FMR LLC now owns 6,888,120 shares of the medical equipment provider’s stock valued at $119,165,000 after acquiring an additional 2,309,559 shares during the period. Goldman Sachs Group Inc. raised its stake in shares of NovoCure Limited by 6,617.7% in the 2nd quarter. Goldman Sachs Group Inc. now owns 4,988,007 shares of the medical equipment provider’s stock valued at $86,293,000 after acquiring an additional 4,913,755 shares during the period. Vanguard Group Inc. raised its stake in shares of NovoCure Limited by 40.5% in the 2nd quarter. Vanguard Group Inc. now owns 4,283,862 shares of the medical equipment provider’s stock valued at $74,111,000 after acquiring an additional 1,235,922 shares during the period. State Street Corp raised its stake in shares of NovoCure Limited by 17.0% in the 2nd quarter. State Street Corp now owns 1,082,589 shares of the medical equipment provider’s stock valued at $18,728,000 after acquiring an additional 157,642 shares during the period. Finally, Frontier Capital Management Co. LLC purchased a new position in shares of NovoCure Limited in the 2nd quarter valued at $14,308,000. 36.84% of the stock is currently owned by institutional investors and hedge funds.

A number of research analysts have weighed in on NVCR shares. Zacks Investment Research lowered shares of NovoCure Limited from a “buy” rating to a “hold” rating in a research note on Tuesday, August 1st. BidaskClub raised shares of NovoCure Limited from a “buy” rating to a “strong-buy” rating in a research note on Monday, July 31st. Mizuho started coverage on shares of NovoCure Limited in a research note on Wednesday, September 6th. They issued a “buy” rating and a $25.00 target price on the stock. Deutsche Bank AG reissued a “hold” rating and issued a $19.00 target price (up from $18.00) on shares of NovoCure Limited in a research note on Monday, July 17th. Finally, ValuEngine raised shares of NovoCure Limited from a “sell” rating to a “hold” rating in a research note on Saturday, June 3rd. Three analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $20.00.

NovoCure Limited Company Profile

NovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a cancer treatment centered on a therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Its TTFields delivery system is used for the treatment of glioblastoma (GBM) and to advance programs testing of TTFields in multiple solid tumor indications through its clinical pipeline.

Insider Buying and Selling by Quarter for NovoCure Limited (NASDAQ:NVCR)

Receive News & Ratings for NovoCure Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovoCure Limited and related companies with MarketBeat.com's FREE daily email newsletter.